Inquiry Basket
CAS No.:
Cat No.: BADC-00726
4.5 
OSu-PEG4-vc-PAB-DMEA-Duocarmycin SA is a drug-linker conjugate for ADC by using Duocarmycin SA (a potent antitumor antibiotic), linked via OSu-PEG4-vc-PAB-DMEA.
Structure of
* For research and manufacturing use only. We do not sell to patients.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
OSu-PEG4-vc-PAB-DMEA-Duocarmycin SA is a potent ADC Cytotoxin with Linker designed for precise intracellular delivery of the Duocarmycin SA payload. The molecule incorporates a cleavable vc-PAB ADC Linker and a PEG4 spacer, enabling stability during systemic circulation and efficient release of the ADC payload inside target tumor cells. As a defined ADC Cytotoxin, it delivers the highly cytotoxic Duocarmycin SA to antigen-expressing cells, supporting DNA alkylation and cell apoptosis while maintaining controlled release through the linker system.
The mechanism of OSu-PEG4-vc-PAB-DMEA-Duocarmycin SA involves antibody-mediated targeting of tumor-associated antigens and subsequent internalization into malignant cells. Once inside the lysosome, the vc-PAB linker is cleaved by proteases, releasing the Duocarmycin SA payload. This selective intracellular release ensures the ADC payload exerts its DNA-alkylating activity specifically within tumor cells, reducing systemic exposure while maximizing cytotoxic efficiency. The PEG4 spacer contributes to solubility and flexibility, facilitating effective conjugation and functional activity.
OSu-PEG4-vc-PAB-DMEA-Duocarmycin SA supports stable conjugation to monoclonal antibodies through its OSu functional group, producing homogeneous ADC Cytotoxins with Linker suitable for reproducible cytotoxic performance. The cleavable linker and PEG4 spacer ensure predictable intracellular release and payload activity, allowing controlled delivery of the Duocarmycin SA moiety. Its chemical design provides both stability in circulation and precise intracellular activation, which is critical for ADC performance.
Applications of OSu-PEG4-vc-PAB-DMEA-Duocarmycin SA are focused on its role as a defined ADC payload-linker combination for constructing antibody-drug conjugates. The protease-sensitive vc-PAB linker and PEG4 spacer facilitate predictable intracellular release of Duocarmycin SA, supporting consistent DNA alkylation and cytotoxic activity. This reagent is essential for generating homogeneous ADC Cytotoxins with Linker that deliver potent, targeted cytotoxic effects for precision oncology applications.
| Catalog | Product Name | CAS | Inquiry |
|---|---|---|---|
| BADC-00811 | Duocarmycin DM free base | 1116745-06-2 | |
| BADC-00337 | Seco-Duocarmycin TM | 1142188-60-0 | |
| BADC-00223 | Duocarmycin A | 118292-34-5 | |
| BADC-00362 | Duocarmycin B1 | 124325-93-5 | |
| BADC-00341 | Seco-Duocarmycin SA | 152785-82-5 | |
| BADC-00605 | Duocarmycin TM | 157922-77-5 | |
| BADC-00332 | Seco-DuocarmycinCN | 1613286-54-6 | |
| BADC-00333 | Seco-DuocarmycinDMG | 1613286-55-7 | |
| BADC-00342 | Seco-Duocarmycin MA | 1613286-57-9 | |
| BADC-00609 | Duocarmycin MB | 1613286-58-0 |
What is OSu-PEG4-vc-PAB-DMEA-Duocarmycin SA?
OSu-PEG4-vc-PAB-DMEA-Duocarmycin SA is a duocarmycin-based cytotoxic agent equipped with a valine-citrulline (vc) cleavable linker, a para-aminobenzyl (PAB) self-immolative spacer, and a PEG4-DMEA solubilizing group. It is designed for conjugation to antibodies in ADCs.
9/3/2019
Dear team, how does the OSu-PEG4-vc-PAB-DMEA-Duocarmycin SA linker function?
The vc dipeptide linker in OSu-PEG4-vc-PAB-DMEA-Duocarmycin SA is specifically cleaved by cathepsin B within lysosomes. After cleavage, the PAB spacer undergoes self-immolation, releasing the active duocarmycin payload for DNA alkylation.
29/8/2020
Dear team, what advantages does PEG4-DMEA provide in this ADC payload?
PEG4-DMEA enhances aqueous solubility and reduces aggregation of the conjugate, improving pharmacokinetics and allowing for higher drug-to-antibody ratios in ADC formulations without compromising stability or efficacy.
8/8/2022
Could you please let me know if OSu-PEG4-vc-PAB-DMEA-Duocarmycin SA can be used in both human and murine ADC models?
Yes, the chemical structure of OSu-PEG4-vc-PAB-DMEA-Duocarmycin SA is compatible with antibodies from multiple species, facilitating preclinical studies in murine models as well as potential translation to human ADCs.
5/8/2022
Dear BOC Sciences, what is the primary application of OSu-PEG4-vc-PAB-DMEA-Duocarmycin SA in research?
This payload is widely used in ADC research for targeting cancer cells. It allows evaluation of linker stability, payload release efficiency, and cytotoxic potency in both in vitro and in vivo oncology models.
15/9/2022
— Dr. Laura Bennett, Senior Chemist (UK)
OSu-PEG4-vc-PAB-DMEA-Duocarmycin SA performed flawlessly in our ADC conjugations, with high solubility and minimal aggregation.
8/8/2022
— Mr. Thomas Wagner, Bioconjugation Scientist (Germany)
The batch quality of OSu-PEG4-vc-PAB-DMEA-Duocarmycin SA was outstanding, enabling consistent DAR values.
15/9/2022
— Dr. Emily Carter, ADC Lead Scientist (USA)
Excellent linker stability and easy handling. OSu-PEG4-vc-PAB-DMEA-Duocarmycin SA met our stringent research requirements.
5/8/2022
— Prof. Hans Müller, Medicinal Chemistry (Switzerland)
Smooth integration of OSu-PEG4-vc-PAB-DMEA-Duocarmycin SA into our workflow. Documentation was clear and thorough.
9/3/2019
— Dr. Isabelle Laurent, Research Chemist (France)
High purity OSu-PEG4-vc-PAB-DMEA-Duocarmycin SA with excellent batch-to-batch consistency, crucial for preclinical studies.
— Mr. David Miller, Conjugation Specialist (USA)
Reliable and reactive linker; OSu-PEG4-vc-PAB-DMEA-Duocarmycin SA supported reproducible conjugation across multiple trials.
29/8/2020
OSu-PEG4-vc-PAB-DMEA-Duocarmycin SA
Required fields are marked with *
OSu-PEG4-vc-PAB-DMEA-Duocarmycin SA
Required fields are marked with *
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.
